CHEMOTHERAPY OF 40 PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS
(Abstract release date: 05/19/16)
EHA Library. MANGASAROVA Y. 06/09/16; 132533; E984
Mrs. Yana MANGASAROVA
Contributions
Contributions
Abstract
Abstract: E984
Type: Eposter Presentation
Background
Primary mediastinal B-cell lymphoma (PMBCL) amounts from 0,9 to 4% of Non-Hodgkin Lymphomas. Predominantly suffer young women. All relapses in PMBCL occur as early events. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL (2-year overall survival (OS) is about 15% [Kurvilla J., 2008]), it’s necessary to achieve a complete remission (CR) in first line treatment.
Aims
To evaluate an efficacy of R-DA-EPOCH therapy + R-DHAP№2 and autologous peripheral blood stem cell transplantation (autoSCT) with BEAM conditioning regimen in treatment of PMBCL pts.
Methods
In 40 pts (14 males, 26 females) diagnosis of PMBCL was established according to WHO criteria. All pts had stage II of disease according to Ann Arbor classification. Median age of pts was 27 years old (from 19 to 67 years old). Increased LDH concentration was revealed in 34 from 40 (85%) pts. Bulky mediastinal disease was in 31/40 (77.5%) pts. In case of CR after 6 courses according to computer tomography and PET scanning treatment was completed. In case of PR pts underwent 2 R-DHAP courses with autoSCT (BEAM conditioning regimen). All cases of treatment failure occurred till one year of observation. Kaplan-Meier method was used to calculate OS and OFS.
Results
After 6 R-DA-EPOCH therapy CR was achieved in 32/40 (80%) pts, 8/40 (20%) pts had PR and underwent 2 R-DHAP courses followed by auto-SCT (BEAM). 2- OFS and OS was 96% and 100%. Early relapse occurred in 1/40 (2,5%) patient. Median follow up was 20 months (3-32).
Conclusion
R-DA-EPOCH allows getting high efficacy of primary mediastinal B-cell lymphoma therapy. Although future analysis will show distant results of R-DA-EPOCH chemotherapy. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL autoSCT in first line therapy might have benefit in patients with partial remission after R-DA-EPOCH.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Chemotherapy, Non-Hodgkin's lymphoma, Rituximab
Type: Eposter Presentation
Background
Primary mediastinal B-cell lymphoma (PMBCL) amounts from 0,9 to 4% of Non-Hodgkin Lymphomas. Predominantly suffer young women. All relapses in PMBCL occur as early events. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL (2-year overall survival (OS) is about 15% [Kurvilla J., 2008]), it’s necessary to achieve a complete remission (CR) in first line treatment.
Aims
To evaluate an efficacy of R-DA-EPOCH therapy + R-DHAP№2 and autologous peripheral blood stem cell transplantation (autoSCT) with BEAM conditioning regimen in treatment of PMBCL pts.
Methods
In 40 pts (14 males, 26 females) diagnosis of PMBCL was established according to WHO criteria. All pts had stage II of disease according to Ann Arbor classification. Median age of pts was 27 years old (from 19 to 67 years old). Increased LDH concentration was revealed in 34 from 40 (85%) pts. Bulky mediastinal disease was in 31/40 (77.5%) pts. In case of CR after 6 courses according to computer tomography and PET scanning treatment was completed. In case of PR pts underwent 2 R-DHAP courses with autoSCT (BEAM conditioning regimen). All cases of treatment failure occurred till one year of observation. Kaplan-Meier method was used to calculate OS and OFS.
Results
After 6 R-DA-EPOCH therapy CR was achieved in 32/40 (80%) pts, 8/40 (20%) pts had PR and underwent 2 R-DHAP courses followed by auto-SCT (BEAM). 2- OFS and OS was 96% and 100%. Early relapse occurred in 1/40 (2,5%) patient. Median follow up was 20 months (3-32).
Conclusion
R-DA-EPOCH allows getting high efficacy of primary mediastinal B-cell lymphoma therapy. Although future analysis will show distant results of R-DA-EPOCH chemotherapy. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL autoSCT in first line therapy might have benefit in patients with partial remission after R-DA-EPOCH.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Chemotherapy, Non-Hodgkin's lymphoma, Rituximab
Abstract: E984
Type: Eposter Presentation
Background
Primary mediastinal B-cell lymphoma (PMBCL) amounts from 0,9 to 4% of Non-Hodgkin Lymphomas. Predominantly suffer young women. All relapses in PMBCL occur as early events. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL (2-year overall survival (OS) is about 15% [Kurvilla J., 2008]), it’s necessary to achieve a complete remission (CR) in first line treatment.
Aims
To evaluate an efficacy of R-DA-EPOCH therapy + R-DHAP№2 and autologous peripheral blood stem cell transplantation (autoSCT) with BEAM conditioning regimen in treatment of PMBCL pts.
Methods
In 40 pts (14 males, 26 females) diagnosis of PMBCL was established according to WHO criteria. All pts had stage II of disease according to Ann Arbor classification. Median age of pts was 27 years old (from 19 to 67 years old). Increased LDH concentration was revealed in 34 from 40 (85%) pts. Bulky mediastinal disease was in 31/40 (77.5%) pts. In case of CR after 6 courses according to computer tomography and PET scanning treatment was completed. In case of PR pts underwent 2 R-DHAP courses with autoSCT (BEAM conditioning regimen). All cases of treatment failure occurred till one year of observation. Kaplan-Meier method was used to calculate OS and OFS.
Results
After 6 R-DA-EPOCH therapy CR was achieved in 32/40 (80%) pts, 8/40 (20%) pts had PR and underwent 2 R-DHAP courses followed by auto-SCT (BEAM). 2- OFS and OS was 96% and 100%. Early relapse occurred in 1/40 (2,5%) patient. Median follow up was 20 months (3-32).
Conclusion
R-DA-EPOCH allows getting high efficacy of primary mediastinal B-cell lymphoma therapy. Although future analysis will show distant results of R-DA-EPOCH chemotherapy. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL autoSCT in first line therapy might have benefit in patients with partial remission after R-DA-EPOCH.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Chemotherapy, Non-Hodgkin's lymphoma, Rituximab
Type: Eposter Presentation
Background
Primary mediastinal B-cell lymphoma (PMBCL) amounts from 0,9 to 4% of Non-Hodgkin Lymphomas. Predominantly suffer young women. All relapses in PMBCL occur as early events. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL (2-year overall survival (OS) is about 15% [Kurvilla J., 2008]), it’s necessary to achieve a complete remission (CR) in first line treatment.
Aims
To evaluate an efficacy of R-DA-EPOCH therapy + R-DHAP№2 and autologous peripheral blood stem cell transplantation (autoSCT) with BEAM conditioning regimen in treatment of PMBCL pts.
Methods
In 40 pts (14 males, 26 females) diagnosis of PMBCL was established according to WHO criteria. All pts had stage II of disease according to Ann Arbor classification. Median age of pts was 27 years old (from 19 to 67 years old). Increased LDH concentration was revealed in 34 from 40 (85%) pts. Bulky mediastinal disease was in 31/40 (77.5%) pts. In case of CR after 6 courses according to computer tomography and PET scanning treatment was completed. In case of PR pts underwent 2 R-DHAP courses with autoSCT (BEAM conditioning regimen). All cases of treatment failure occurred till one year of observation. Kaplan-Meier method was used to calculate OS and OFS.
Results
After 6 R-DA-EPOCH therapy CR was achieved in 32/40 (80%) pts, 8/40 (20%) pts had PR and underwent 2 R-DHAP courses followed by auto-SCT (BEAM). 2- OFS and OS was 96% and 100%. Early relapse occurred in 1/40 (2,5%) patient. Median follow up was 20 months (3-32).
Conclusion
R-DA-EPOCH allows getting high efficacy of primary mediastinal B-cell lymphoma therapy. Although future analysis will show distant results of R-DA-EPOCH chemotherapy. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL autoSCT in first line therapy might have benefit in patients with partial remission after R-DA-EPOCH.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Chemotherapy, Non-Hodgkin's lymphoma, Rituximab
{{ help_message }}
{{filter}}